🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Exclusive-Thermo Fisher, Celltrion vie for Baxter's biopharma unit -sources

Published 03/20/2023, 05:43 PM
Updated 03/21/2023, 11:51 AM
© Reuters. FILE PHOTO: The logo of Celltrion is seen at the company's headquarters in Incheon, South Korea, October 28, 2016. REUTERS/Kim Hong-Ji

By Anirban Sen and David Carnevali

(Reuters) -U.S. scientific instruments maker Thermo Fisher Scientific Inc (NYSE:TMO) and South Korea's Celltrion Inc are among those competing to acquire the biopharma solutions business of medical device maker Baxter International Inc (NYSE:BAX), according to people familiar with the matter.

The divestment, which the sources said could fetch more than $4 billion, would help Baxter pay down debt following its $10.5 billion acquisition of medical device maker Hill-Rom (NYSE:HRC) Holdings in 2021. Baxter, which has a market value of $19 billion, had total debt of $16.6 billion as of the end of December.

Private equity firms, including KKR & Co (NYSE:KKR) and Carlyle Group (NASDAQ:CG), have also expressed interest in the Baxter business, the sources said. Other bidders could still emerge, they added.

The sources requested anonymity because the matter is confidential. Baxter, Thermo Fisher and KKR declined to comment. Celltrion and Carlyle did not immediately respond to requests for comment.

Baxter said in January it was exploring alternatives for its biopharma solutions business and would also spin off its kidney care units.

The Deerfield, Illinois-based company focuses on areas such as critical care, surgical products, nutrition and pharmaceutical equipment.

Baxter's biopharma solutions unit supports drugmakers in the formulation, development and commercialization of drugs typically given by infusion or injection, such as biologics and vaccines.

© Reuters. FILE PHOTO: The logo of Celltrion is seen at the company's headquarters in Incheon, South Korea, October 28, 2016. REUTERS/Kim Hong-Ji

Thermo Fisher, one of the world's largest suppliers of scientific equipment, has been making acquisitions in recent years to expand its offerings in contract research and manufacturing, including a $5.2 billion purchase of Patheon NV in 2017 and a $17.4 billion takeover of PPD (NASDAQ:PPD) Inc in 2021.

Celltrion, whose co-founder and chairman Seo Jung-jin is South Korea's richest person according to Forbes, is a biopharmaceutical company that also has a contract research and manufacturing arm.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.